| Name | Title | Contact Details |
|---|---|---|
Garrie Richardson |
Chief Revenue Officer | Profile |
Marcus Schulz |
Chief Revenue Officer | Profile |
Tim Bush |
Vice President - Strategic Supply Chain Management | Profile |
Bill Yang |
Global Director of Product Management | Profile |
Troy Wichterman |
Chief Financial Officer | Profile |
Temporary Technical Services Inc is a Jackson, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Reviva Pharmaceuticals is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario`s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years.